CoChat

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

Open access
Harrington, Bonnie K., Gardner, Heather L., Izumi, Raquel, Hamdy, Ahmed, Rothbaum, Wayne, Coombes, Kevin R., Covey, Todd, Kaptein, Allard, Gulrajani, Michael, Van Lith, Bart, Krejsa, Cecile, Coss, Christopher C., Russell, Duncan S., Zhang, Xiaoli, Urie, Bridget K., London, Cheryl A., Byrd, John C., Johnson, Amy J., Kisseberth, William C. · 2016 · PLOS ONE
Cited by 58

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy similar to human diffuse large B-cell lymphoma (DLBCL). First, we demonstrated that acalabrutinib potently inhibited BTK activity and downstream effectors in CLBL1, a canine B-cell lymphoma cell line, and primary canine lymphoma cells. Acalabrutinib also inhibited proliferation in CLBL1 cells. Twenty dogs were enrolled in the clinical trial and treated with acalabrutinib at dosages of 2.5 to 20mg/kg every 12 or 24 hours. Acalabrutinib was generally well tolerated, with adverse events consisting primarily of grade 1 or 2 anorexia, weight loss, vomiting, diarrhea and lethargy. Overall response rate (ORR) was 25% (5/20) with a median progression free survival (PFS) of 22.5 days. Clinical benefit was observed in 30% (6/20) of dogs. These findings suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0159607

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 58

Metadata

Authors
Harrington, B. K., Gardner, H. L., Izumi, R., Hamdy, A., Rothbaum, W., Coombes, K. R., Covey, T., Kaptein, A., Gulrajani, M., Van Lith, B., Krejsa, C., Coss, C. C., Russell, D. S., Zhang, X., Urie, B. K., London, C. A., Byrd, J. C., Johnson, A. J., & Kisseberth, W. C.
Venue
PLOS ONE
Published
2016-07-19
Volume
11
Issue
7
Pages
e0159607
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2497974852
Cited by
58
References
6
FWCI
7.15
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. https://app.cochat.ai/papers/10.1371/journal.pone.0159607
The paper
Harrington, B. K., Gardner, H. L., Izumi, R., Hamdy, A., Rothbaum, W., Coombes, K. R., Covey, T., Kaptein, A., Gulrajani, M., Van Lith, B., Krejsa, C., Coss, C. C., Russell, D. S., Zhang, X., Urie, B. K., London, C. A., Byrd, J. C., Johnson, A. J., & Kisseberth, W. C. (2016). Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0159607

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.